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ABSTRACT 
Objective: To determine changes in the incidence of dementia between 1988 and 2015. 
 
Methods: This analysis was performed in aggregated data from individuals >65 years in seven 
population-based cohort studies in the United States and Europe from the Alzheimer Cohort 
Consortium. First, we calculated age- and sex-specific incidence rates for all-cause dementia, 
and then defined non-overlapping 5-year epochs within each study to determine trends in 
incidence. Estimates of change per 10-year interval were pooled and results are presented 
combined and stratified by sex. 
 
Results: Of 49,202 individuals, 4,253 (8.6%) developed dementia. The incidence rate of 
dementia increased with age, similarly for women and men, ranging from about 4 per 1,000 
person years in individuals aged 65-69 years, to 65 per 1,000 person years for those aged 85-89 
years. The incidence rate of dementia declined by 13% per calendar decade (95% CI: 7%-19%), 
consistently across studies, and somewhat more pronouncedly in men than in women (24% 
[95% CI 14%-32%] versus 8% [0%-15%]).  
 
Conclusion: The incidence rate of dementia in Europe and North America has declined by 13% 
per decade over the past 25 years, consistently across studies. Incidence is similar for men and 
women, although declines were somewhat more profound in men. These observations call for 
sustained efforts to finding the causes for this decline, as well as determining their validity in 
geographically and ethnically diverse populations. 
 
 6 
Introduction 
At present, an estimated 47 million people worldwide are living with dementia, making it a 
leading cause of dependence and disability.1-3 Because of a rapid aging of populations, the 
number of people living with dementia is projected to triple in the next 30 years, and the 
socioeconomic burden of dementia to increase accordingly. The projected burden of dementia 
could be alleviated if improvements in life conditions and healthcare over the last decades have 
decreased dementia risk. Indeed, recent studies in North America and Europe have reported a 
decline in the incidence of dementia over the last forty years, with possible reductions of 10% to 
38% per decade, but estimates are inconsistent and often imprecise.4-8   
Reliable assessment of time trends in the incidence of dementia calls for careful 
monitoring in the general population, in a consistent manner over a prolonged period of time. 
Population-based cohort studies have generally collected data on dementia incidence over 
decades, but few have been designed and powered to test for differences across calendar time. 
Consequently, individual studies lack the precision to quantify time trends in dementia 
incidence, leaving projections of the future burden of disease uncertain, with the range of 
reported reductions in time trends allowing for a variation of tens of millions new cases of 
dementia in the coming decades. Large heterogeneity, notably in the applied methodology of 
prior analysis of secular trends further hinders comparison and reliable prediction across 
populations.6, 9 In a multinational collaboration, we aggregated data from available long-term 
population-based studies from Europe and the USA to study the trend in dementia incidence, 
and establish whether similar changes were observed in men and women. 
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Methods 
Data sources and study population: the Alzheimer Cohorts Consortium: ACC 
The ACC is composed of nine cohorts selected based on pre-determined criteria. Specifically, 
the included cohorts had to be prospective, population-based, have in-person exams, a span of at 
least 15 years of available follow-up and include at least 2,000 participants at baseline. In 
addition, many cohorts have data on genotype and extensive phenotyping, particularly of 
cardiovascular factors and acquisition of brain magnetic resonance imaging (MRI). The 
consortium includes the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study, the 
Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), 
the Cognitive Function and Ageing Studies (CFAS), the Framingham Heart Study (FHS), the 
Gothenburg population studies, the Personnes Agées QUID (PAQUID) study, the Rotterdam 
Study, and the Three-City Study (3C). More detailed information on the ACC has been 
published previously.10  
 
Standard Protocol Approvals, Registrations, and Patient Consents 
All the participating ACC studies were approved by their respective institutional review 
committees, and all subjects provided written informed consent.  
 
Cohorts 
The present study included seven participating cohorts and data collection summaries are 
presented in Table 1, and include a total of 49,202 (minimum age of 65 at entry) of whom 4,253 
had developed dementia to date. Cohort descriptions have been provided previously.8 Briefly, 
the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study is a sample drawn from the 
population-based Reykjavik Study cohort11. The original source population in the Reykjavik 
Study included a random sample of men and women born between 1907 and 1935 and living in 
Reykjavik in 1967. Between 2002 and 2006, 5,764 survivors of the original cohort were re-
examined for the AGES-Reykjavik study. The Cognitive Function and Ageing Studies (CFAS) 
comprises two population-based studies among individuals aged 65 years and over living in the 
community, including those in institutions.5 The original six-site study began in 1989 (MRC-
CFAS; response 80%), however, interviewing began in 1991 for the three sites that were 
selected for the current comparison study. This comparison study, with independent sampling 
across three similar sites was initiated two decades later, with baseline interviewing undertaken 
from 2008-2010 (CFAS II; response 56%). For this analysis, the baseline and two-year follow-
up data are included. The Framingham Heart Study (FHS) began in 1948 with the recruitment 
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of an original cohort of 5,209 men and women who were 28 to 62 years of age at entry.12 In 
1971, a second generation of study participants, including 5,124 children and spouses of 
children of the original cohort were enrolled.13 The Gothenburg population studies consist of 
four studies among individuals representative of the Swedish population.14, 15 These include 
Prospective Population Study of Women, a study of women which includes 1,462 women aged 
38-60 who are followed since 1968; the Gothenburg H70 Birth Cohort Studies, which studies 
several birth cohorts of 70-year olds recruited from 1971 and onwards of which a cohort of 70-
years olds enrolled in 2000 were included in this study; and the second H85 study, which started 
in 2009 with the enrolment of a birth cohort of 85-year olds. The Personnes Agées QUID 
(PAQUID) cohort is a population-based study in the southwest of France among 3,777 
individuals aged 65 years or older recruited in 1988.16 There have been twelve subsequent 
waves of data collection at 1, 3, 5, 8, 10, 13, 15, 17, 20, 22, 25 and 27 years after the baseline 
assessment. Due to changes in diagnoses over the first years of follow-up, for trends analysis, 
only data from the 8-year follow-up was included.17 The Rotterdam Study (RS) is a prospective 
population-based cohort study comprising 14,926 subjects aged 45 years or older.18 Baseline 
data of 7,983 participants were collected between 1990 and 1993 (response 78%), with 
subsequent cohort expansions in 2000 (3,011 individuals, 67%) and 2006 (3,236 individuals, 
65%). Participants are interviewed at home and re-examined at a dedicated research center once 
every 4 years. In addition, the entire cohort is continuously under surveillance for disease 
outcomes through linkage of electronic medical records with the study database. The Three-City 
Study (3C) is a longitudinal population-based study of the relation between vascular diseases 
and dementia in persons aged 65 years and older.19 Between 1999 and 2001, a total of 9 294 
non-institutionalized persons were recruited from the electoral rolls of three French cities: 
Bordeaux (South-West), Dijon (North-East) and Montpellier (South-East). Extensive follow-up 
examinations were performed at home or in a dedicated research center every two years after the 
baseline assessment, comprising standardized questionnaires, clinical examinations, and detailed 
cognitive assessment. An overview of the study populations is presented in Table 1.  
The Atherosclerosis Risk in Communities (ARIC) study and the Cardiovascular Health 
Study (CHS), which are also part of the ACC, were not included in these analyses as ARIC did 
not have sufficient follow-up at the time of these analyses, and the CHS had consistent data on 
long-term follow-up available in only a small subset of the (Pittsburgh) population only.  
 
Assessment of Dementia and Alzheimer’s Disease  
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Our primary outcome of interest is a diagnosis of all-cause dementia with a secondary outcome 
of clinical Alzheimer’s Disease, where available. Dementia diagnostic criteria were consistent 
across the study period for each study, and are based on either Diagnostic and Statistical Manual 
– IIIR (DSM-IIIR) (CFAS, Gothenburg studies, PAQUID and the Rotterdam study) or DSM-IV 
(AGES, FHS and 3C). The National Institute of Neurological and Communicative Disorders and 
Stroke – Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria20 
for Alzheimer’s disease diagnosis was used in all cohorts except CFAS and the Gothenburg 
studies, which did not have data on Alzheimer’s diagnosis.  
 
Statistical Analysis  
Poisson regression was used to calculate 5-year incidence rates (IRs) and 95% confidence 
intervals. All models were adjusted for age at time of entry and sex, and the log of follow-up 
time was used as an offset variable with incidence rates presented for the middle age of each 5-
year age group (e.g. for 65 to 69.9 age group we used the middle age of 67.5). A single 
participant was able to contribute to multiple age groups as long as that person is free from 
dementia at the start of the age-group category. A robust sandwich estimator was used to 
calculate the 95% confidence interval to control for the violation of the independence 
assumption21. Additionally, models for all-cause dementia were stratified by age and sex. Due to 
limited data and follow-up among men, the Gothenburg studies included only women for these 
analyses. For comparison between men and women, results from the sex-specific incidence rates 
were analysed across all cohorts using the “meta”-package (version 4.8-4) of the statistical 
software R, version 3.4.2 with heterogeneity across studies being assessed with an I2 statistic. 
Cohorts with sufficient follow-up data to create at least two epochs were included in the 
trends analysis. Cohort-specific, non-overlapping epochs were created in order to maximize the 
person-years available in each cohort, with two epochs in the Three-City study, three epochs in 
PAQUID, the Rotterdam Study and the Gothenburg studies, and four epochs in FHS. Cox 
proportional hazard regression models were used to calculate the 5-year cumulative hazards per 
epoch, and hazard ratios (HR) for all-cause dementia and Alzheimer’s disease for each epoch 
relative to the first. In CFAS Bayesian full likelihood imputation models were used to adjust for 
study design of CFAS I.22 All models were adjusted for age at entry of the epoch and sex, with 
the exception of the sex-stratified models, which were adjusted solely for age. Participants were 
included in an epoch if they were free of dementia at the beginning of the epoch, and censored at 
the end of five years, at their last visit, when lost to follow-up or at date of death, whichever 
came first. Similar to the incidence analyses, participants contributed to multiple epochs if they 
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were free of dementia at the beginning of the epoch and we utilized a robust sandwich estimator 
for the covariance structure to estimate the 95% confidence limits to account for non-
independence21. To compare temporal trends across studies, we then calculated a hazard ratio 
per 10-year change in calendar time. This is interpreted as a change in 5-year hazard per decade 
advance in calendar time and was estimated using years from the median date of the referent 
first epoch to the median start date of each epoch, divided by ten and treated as a continuous 
variable in the model. This assumes the time trend is constant across the 25-year study period. 
Trends were meta-analysed across all cohorts, with heterogeneity across studies assessed with 
an I2 statistic using the “meta”-package (version 4.8-4) of the statistical software R, version 
3.4.2. To rule out any dominant effect of the largest studies on the pooled estimate, we 
performed sensitivity analyses in which we excluded one by one the studies with the largest 
weight until a minimum of three studies.   
To visualize the impact of changing incidence in dementia both globally and within 
Europe and the USA, we used data from the 2012 and 2015 World Alzheimer Reports to 
estimate how a decreasing trend in incidence would impact the expected number of new cases 
per year by 2040. We used the change in total cases/year between 2010 and 2015 and 
extrapolated that same change for each 5-year interval, taking into account the increasing 
population size and increasing longevity through to 2040, which resulted in similar projections 
as given in the 2012 report. We then estimated the effect of a continued decline in incidence on 
the total number of new dementia cases until 2040, assuming effect estimates for time trends 
from the present study.  
All analyses were done separately by investigators responsible for each cohort. In order 
to ensure harmonization in analyses, each cohort received a detailed analysis plan, including 
statistical code in both SPSS (IBM Corp., Armonk, NY) and SAS (SAS Institute, Cary, NC).  
 
Data availability statement 
Framingham Study data are available through BioLINCC, where qualified researchers can apply 
for authorization to access (https://biolincc.nhlbi.nih.gov/studies/framcohort/?q=Framingham). 
Data of European cohorts are available upon request, after approval by the relevant institutional 
review boards, in keeping with informed consent and the national and EU data protection 
regulations. Request can be directed at the following contacts: for AGES, the Icelandic Heart 
Association (AGES_data_request@hjarta.is); for the Rotterdam Study, data manager Frank J.A. 
van Rooij (f.vanrooij@erasmusmc.nl); for CFAS, the national co-ordinator of the CFAS 
Collaboration Data Archive, Linda Barnes (leb22@medschl.cam.ac.uk); for 3C, the principle 
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investigator Dr. Christophe Tzourio (E3C.CoordinatingCenter@gmail.com or 
christophe.tzourio@u-bordeaux.fr); for PAQUID, the coordinating investigator Dr. Catherine 
Helmer (catherine.helmer@u-bordeaux.fr); for the Gothenburg Studies, the principal 
investigator Dr. Ingmar Skoog (Ingmar.Skoog@neuro.gu.se). 
 
Results 
Cohort characteristics, and demographics of participants in the analyses per cohort are presented 
in Table 1. Data on nearly 50,000 participants with 2 to 27 years of follow-up are included in 
this study. All the cohorts comprise more women than men with a mean relative frequency of 
59%. Mean age at baseline of the first epoch was between 71 and 77 for all cohorts (Table 1).  
A total of 49,202 participants were included in the incidence analyses and followed for a 
total of 256,805 person-years. A total of 4 253 incident cases of dementia were recorded in the 
data analysed for the included cohorts (Table 1). Across all cohorts, incidence rates by age 
group were consistent (Table 2). As expected, the incidence of dementia increased with age, 
from 1.6 to 8.6 per 1,000 person-years in the youngest age group (65-69 years), to between 42.2 
and 97.0 per 1,000 person-years in the oldest age group (85-89 years). In general, the CFAS II 
cohort and the FHS had the lowest incidence rates and the Rotterdam Study observed the highest 
(Figure 1). This pattern was similar for the sex-specific results. When results were combined 
across cohorts, we saw little difference in incidence rates by age group, or between men and 
women (Figure 2).  
We directly compared and analysed the 5-years hazard ratios per 10-year increment in 
calendar time between cohorts. This showed a consistent decrease in the 5-year cumulative 
hazard of all-cause dementia in all cohorts (Figure 3A; Table 3). Across studies, we saw a 13% 
(95% CI: 7-19%) decrease in all-cause dementia per decade since 1990. Patterns were similar, 
for clinical Alzheimer’s disease (decrease per decade: 16% [8-24%]; Figure 3B). The decrease 
in 5-year cumulative hazard for all-cause dementia was larger in men than women, with a 24% 
decrease [14-33%] in men versus an 8% decrease [0-15%] in women, again with little 
heterogeneity across studies (I2=0% and 5%, respectively) (Figure 3C and 3D). Results were 
broadly unaltered by stepwise excluding the three studies with the largest weight, with hazard 
ratios (95% CI) of 0.84 (0.78-0.92), 0.87 (0.77-0.97), and 0.82 (0.71-0.95), after exclusion of 
respectively CFAS, CFAS and RS, and CFAS, RS, and FHS. 
 
Discussion 
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In this analysis of data from seven large cohort studies representing populations from six 
different countries, we show that the age-stratified incidence rates of dementia are consistent 
across cohorts and notably similar between men and women. When examining changes in the 
incidence rate over the past 25 years, we observe a decline of 13% per decade, again consistent 
across studies, but somewhat stronger for men compared to women. If we assume continuation 
of this trend in Europe and North America into the coming decades – although this was not the 
main objective of our study – it could imply that 15 million fewer people will develop dementia 
by 2040 in high-income countries, compared to widely quoted projections of the global burden 
of disease.23 If the same continuous incidence reduction could be achieved worldwide, this could 
lead to a reduction in the expected incidence of dementia of up to 60 million new cases of 
dementia by 2040 (Figure 4). 
Several of the cohorts within the ACC have previously published data on time trends in 
the incidence of dementia.4, 5, 7, 8 The incidence trends described here are an important step 
towards consensus, with substantially greater precision arising from using consistent analytical 
techniques across cohorts. In addition, our analyses suggest that these time-trends in dementia 
incidence have occurred in both men and women. However, the effects of this decline in age-
specific incidence will also depend on concurrent changes in life-expectancy.24 Reductions in 
years spent with cognitive disability in the UK from 1991 to 2011,5 and reductions in years lived 
with dementia in the USA over the last 30 years7 raise hope that preventive efforts involving 
lifestyle and health care interventions against dementia can offset at least part of the growing 
burden of dementia with from global gains in life-expectancy.  
The study has strengths and limitations. First and foremost, this analysis has greater 
precision derived from combining several large, long-term population-based cohorts that have 
strived to limit person attrition from the studies over many years. We have described 
methodological considerations for studying trends in the incidence of dementia previously10. It 
is important to note that despite inevitable differences in population demographics, genetic and 
lifestyle make-up, and ascertainment methods for dementia, incidence trends displayed 
relatively little heterogeneity across studies. Further, concurrent increases in life expectancy and 
increased awareness of dementia in the population may have led to underestimation of a 
downward trend arising from increased diagnosis efficiency.  
As a first limitation, despite extensive efforts to limit attrition, differential dropout may 
have occurred when linkage to health records was not available. However, attrition that is 
constant over time is unlikely to affect secular trends. Second, while the definition of dementia 
as a syndrome has remained relatively constant, the definition and understanding of what should 
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be called Alzheimer’s disease have shifted substantially over the past decades. In the absence of 
pathologically confirmed diagnoses in most cohort studies, it remains uncertain what 
pathological changes may underlie the observed trends. Third, calculating the effect of the 
observed trends on future dementia incidence relies on various assumptions that were beyond 
the scope of the current study to address entirely, and studies applying multistate modelling 
remain required for accurate projections in light of changing risk factor burden and mortality. 
Fourth, the application of consistent entry criteria helped guarantee valid assessment of 
incidence trends, but may have led to selection of a somewhat healthier population and 
consequently underestimation of absolute incidence rates. Finally, the choice to limit our 
analyses to population-based cohorts in order to get the most accurate measure of population 
incidence, has led to a study population containing only those of European ancestry living in 
either the United States or Europe, with a generalizability of our findings to no more than 16% 
of the world’s total population. These analyses should therefore be expanded to include (future) 
population studies with more diverse populations both within the United States and around the 
globe.    
A main challenge in finding a cause of declining temporal trends in dementia is that 
there have been many concurrent changes over time in possible key risk factors, including 
lifestyle education and health interventions such as blood pressure control and antithrombotic 
medication. While none of these have been specifically intended to halt cognitive decline, 
decades of cardiovascular risk management have likely had substantial effects on brain health, 
supported by reduction of small-vessel disease on brain imaging in more recent years.8 The 
challenge remains to identify the critical causal factors among a variety of interventions 
influencing blood pressure, cholesterol, and inflammation that may have contributed to the 
decrease. Improved access and provision of education is another major change over the past 
century that could explain decreasing dementia incidence rates over time.25  
Contrasting reports on the incidence of dementia have emerged recently from Japan,26 
China,27 and Nigeria,28 showing stable, or even increasing incidence rates. Similarly, in multi-
ethnic populations in the USA declines have been seen in some,29 but not all studies.30 Against 
the backdrop of the large expected increases in dementia burden, particularly in Asia and 
Africa,23 these observations temper the optimism for low to middle income countries, and render 
it all the more necessary to unravel the causes underlying the trends seen in this present study. 
Comparison with other geographical regions may well aid in pinpointing similar or discordant 
trends. Overall increased ethnic and geographic diversity within the ACC and the wider research 
community is therefore an important ongoing goal. 
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The development we see now in the epidemiology of dementia is somewhat reminiscent 
of the first report of a decline in mortality from coronary heart disease in 1964.31 If history has 
taught us anything in that respect, it is the need for prolonged, consistent surveillance of disease 
and associated factors to enable the future modelling of trends and the identification of causes.9, 
31
 Similar to heart disease31, we should caution that the rise on a global scale of obesity,32 
diabetes,33 and hypertension,34 may reverse trends in dementia over the coming decades. As 
such, continued surveillance for dementia in the population-based studies within the ACC 
provides the framework for further investigation of potential causes of the declining time-trend 
in dementia incidence. 
 
In conclusion, the incidence of dementia in Europe and North America is very similar among 
men and women and has declined by 13% per decade over the past three decades. Identification 
of the underlying causes is vital to sustain and possibly enhance these trends in the face of 
changing risk factor profiles. It is essential to achieve equal reductions in areas of the world 
where projected increases in dementia burden are steep, and improvements in incidence thus far 
absent. 
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Table 1: Demographics and Characteristics of cohorts  
Study PAQUID 
Rotterdam 
Study 
Framingham 
Heart Study 
Gothenburg 
Studies CFAS I CFAS II 
Three-City 
Study AGES, Reykjavik 
Country France Netherlands USA Sweden UK UK France Iceland 
Sample Size 2,960 10,235  2,596 1,168 6,441 11,788 8,250 5,764 
Dementia follow-up, y 27 25 25 23 2 2 13.5 6 
Mean age, y 75.3 71.4 72.1 76.1 76.4 76.0 74.0 77.0 
Women, % 58.0% 58.0% 59.2% 100% 61.6% 56.1% 61.3% 57.7% 
Caucasian ethnicity, % a 98.6% 100% a 99.1% 97.2% 100% 100% 
Person-Years 19,314 74,517 29,906 6,368 12,850 25,319 64,561 23,970 
Incident dementia 578 766 685 145 261 390 951 477 
Incident AD 455 521 540 a a a 653 150 
a
 Data not collected  
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Table 2: Incidence rates (per 1000 persons) by cohort, age groups and sex 
 PAQUID Rotterdam Study Framingham 
Heart Study 
Gothenburg 
Studies 
CFAS I CFAS II 
Three-City 
Study 
AGES Reykjavik 
Sample Size 4498 10235 1986 1168 6441 11788 12845 5135 
Person-Years 18513 74517 20615 6368 12850 25319 53808 22386 
Incident Dementia 491 766 592 145 261 390 634 369 
Age Groups         
65-69 3.2 (1.8-5.5) 5.7 (4.0-8.1) 1.6 (0.6-4.5) N/A 8.6 (5.2-14.2) 5.0 (3.0-8.7) 2.0 (0.1-0.3) 4.5 (2.7-6.5) 
70-74 5.9 (3.6-9.3) 19.5 (15.7-22.4) 9.7 (7.1-13.3) 8.0 (5.4-11.8) 11.0 (6.8-17.7) 8.2 (5.4-12.6) 6.3 (0.5-0.8) 7.9 (6.4-9.5) 
75-79 26.5 (22.2-31.5) 37.2 (31.3-44.3) 17.9 (1.4-2.2) 18.6 (10.2-33.6) 18.6 (11.7-29.4) 16.4 (11.4-23.6) 12.8 (1.3-1.5) 15.7 (13.4-18.1) 
80-84 43.6 (37.6-50.6) 58.3 (48.3-70.4) 41.0(3.5-48.4) 43.2 (29.6-62.9) 41.2 (29.3-57.9) 32.1 (23.4-44.1) 23.1 (2.0-2.7) 37.3 (33.3-41.5) 
85-89 73.1 (62.3-85.9) 97.0 (76.9-122.2) 67.9 (56.5-81.5) 73.3 (27.1-200.9) 56.3 (38.9-81.4) 42.2 (28.3-62.7) 48.2 (4.0-5.8) 66.3 (56.3-76.8) 
Men Only 
Sample Size 1826 4296 782 N/A 2279 5575 4834 2177 
Person-Years 7491 30849 7685 N/A 4533 11961 19626 9177 
Incident Dementia 158 271 188 N/A 95 173 214 155 
Age Groups         
65-69 5.1 (2.6-9.8) 7.3 (4.3-12.5) 3.4 (1.5-7.3) N/A 10.9 (5.7-20.6) 5.4 (2.6-11.3) 2.3 (0.1-0.5) 4.1 (1.5-7.2) 
70-74 7.5 (4.0-14.0) 19.2 (14.0-26.4) 7.8 (5.1-11.8) N/A 14.8 (8.0-27.5) 10.1 (5.8-17.6) 7.0 (0.5-1.0) 7.0 (4.9-9.3) 
75-79 25.6 (19.3-33.9) 43.5 (33.1-57.2) 22.6 (17.6-29.0) N/A 22.0 (8.1-59.2) 13.6 (7.0-26.6) 11.8 (0.9-1.5) 16.8 (13.3-20.6) 
80-84 31.2 (23.3-41.8) 57.1 (41.8-78.0) 25.0 (18.7-33.2) N/A 47.3 (27.6-81.2) 22.3 (12.4-38.9) 19.3 (1.5-2.6) 39.8 (33.1-46.4) 
85-89 58.7 (42.7-80.5) 118.9 (76.5-184.8) 73.6 (57.0-95.1) N/A 70.4 (35.8-138.3) 37.7 (22.4-63.4) 49.0 (3.5-6.9) 62.1 (45.1-76.2) 
Women Only 
Sample Size 2672 5939 1204 1168 4163 6914 8011 2958 
Person-Years 11022 43668 12930 6368 8317 14787 33183 13209 
Incident Dementia 333 495 404 145 166 300 420 214 
Age Groups         
65-69 1.6 (0.6-4.5) 4.6 (2.9-7.4) 1.7 (0.6-4.6) N/A 6.4 (3.0-13.7) 4.7 (2.1-10.2) 1.8 (0.1-0.4) 4.7 (2.4-7.3) 
70-74 4.4 (2.0-9.4) 19.7 (14.6-26.4) 9.2 (6.5-13.0) 8.0 (5.4-11.8) 7.9 (3.8-16.2) 6.1 (3.0-12.4) 5.7 (0.4-0.8) 8.5 (6.5-10.7) 
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75-79 27.1 (21.6-33.9) 33.4 (26.6-41.9) 17.8 (14.2-22.3) 18.6 (10.2-33.6) 17.5 (10.5-29.2) 16.8 (10.6-26.8) 13.4 (1.1-1.6) 14.9 (11.9-18.0) 
80-84 50.7 (42.7-60.1) 58.6 (46.2-74.4) 41.0 (34.8-48.4) 43.2 (29.6-62.9) 37.6 (24.6-57.3) 39.3 (26.7-57.6) 29.0 (2.1-3.0) 35.8 (30.8-41.2) 
85-89 80.3 (66.7-96.6) 89.2 (68.0-116.9) 67.9 (56.4-81.6) 73.3 (27.1-200.9) 50.6 (32.6-78.5) 45.8 (30.0-69.9) 47.8 (3.8-6.0) 68.8 (57.3-83.7) 
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Table 3: Change in incidence per decade (HR, 95% CI) by study and sex  
 PAQUID 
Rotterdam 
Study 
Framingham 
Heart Study 
Gothenburg 
Studiesa 
CFAS I/II 3 Cities 
Meta-Analysis 
(random-effects) 
All cause dementia 0.75 (0.60-0.94) 0.82 (0.73-0.93) 0.93 (0.79-1.11) 0.84 (0.60-1.18) 0·93 (0.82-1.05) 0.90 (0.71-1.13) 0.87 (0.81-0.93) 
Alzheimer's Disease 0.70 (0.55-0.89) 0.85 (0.74-0.98) 0.85 (0.71-1.03)   0.95 (0.72-1.25) 0.84 (0.76-0.92) 
Sex        
Men 0.60 (0.39-0.91) 0.78 (0.63-0.97) 0.86 (0.64-1.16) N/A 0.78 (0.63-0.97) 0.67 (0.45-1.00) 0.76 (0.67-0.86) 
Women 0.82 (0.63-1.07) 0.84 (0.72-0.97) 0.97 (0.78-1.20) 0.84 (0.60-1.18) 1.02 (0.86-1.19) 1.04 (0.78-1.37) 0.92 (0.85-1.00) 
a
 Includes only women 
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Figure 1.  
Title: Incidence rates of dementia, stratified by cohort and age group 
 
Figure 2. 
Title: Incidence rates of dementia by age group, comparing men vs. women 
 
Figure 3.  
Title: Trends in the incidence of dementia 
Caption: The forest plots represent the incidence trend for (a) all-cause dementia, (b) Alzheimer’s disease, (c) all-cause dementia in men, and (d) all-cause 
dementia in women, expressed as a hazard ratio per 10-year advance in calendar time. This hazard ratio was calculated to compare temporal trends across 
studies, and can be interpreted as a change in the 5-year hazard per decade advance in calendar time. 
 
Figure 4. 
Title: Projected incidence of dementia in millions 
Caption: Projected incidence of dementia on the basis of current rates (solid lines) and projected incidence of dementia assuming continuation of a decreasing 
trend (dashed lines). Current rates are based on estimates from the 2012 World Alzheimer Report, which at the time estimated that 682 million new cases 
would occur over the 2010-2050 period.  
 
 




